Publications

Select keywords to filter the posts for matching content:

Keywords
Topics
  • Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.
    V. Müller, M. Banys-Paluchowski, T.W.P. Friedl, P.A. Fasching, A. Schneeweiss, A. Hartkopf, D. Wallwiener, B. Rack, F. Meier-Stiegen, J. Huober, M. Rübner, O. Hoffmann, L. Müller, W. Janni, P. Wimberger, B. Jäger, K. Pantel, S. Riethdorf, N. Harbeck, T. Fehm, DETECT study group
    PMID: 34839105 Show Details link to full text
    Study

    DETECT

    Year

    2021

    Keywords
    • breast cancer
    • liquid biopsy
    • HER2
    • oncology
  • Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months.
    N. Teich, H. Grümmer, E. Jörgensen, T. Liceni, F. Holtkamp-Endemann, T. Fischer, S. Hohenberger
    PMID: 33845784 Show Details link to full text
    Study

    Go CUTE II

    Year

    2021

    Keywords
    • golimumab
    • ulcerative colitis
    • QoL
    • WPAI
    • HCRU
  • Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study i
    N. Teich, M. Bläker, F. Holtkamp-Endemann, E. Jörgensen, A. Stallmach, S. Hohenberger
    PMID: 33850839 Show Details link to full text
    Study

    MC Productive

    Year

    2021

    Keywords
    • Crohn's disease
    • infliximab
    • QoL
    • WPAI
    • HRQoL
  • Neoadjuvant and adjuvant end-points in health technology assessment in oncology.
    N. Harbeck, A. Schneeweiss, P. Thuss-Patience, K. Miller, C. Garbe, F. Griesinger, W. E. E. Eberhardt, J. P. Klussmann, B. Wollenberg, M. O. Grimm, T. Zander, D. Lüftner
    PMID: 33611103 Show Details link to full text
    Study

    AMNOG

    Year

    2021

    Keywords
    • immunotherapy
    • oncology
  • Switching COPD patients from the disposable to the new reusable Respimat soft mist inhaler: a real-world study from Switzerland
    A. Tschacher, C. Cadus, S. Schildge, J. P. Diedrich, P. N. Chhajed, A. B. Leuppi-Taegtmeyer, J. D. Leuppi
    PMID: 34433362 Show Details link to full text
    Study

    NTA Switch

    Year

    2021

    Keywords
    • Respimat inhaler
    • COPD
  • Klinisches Managment von PARP-Inhibitoren
    B. Schmalfeldt
    PMID: Show Details link to full text
    Study

    Year

    2021

    Keywords
    • PARP inhibitors
    • ovarian cancer
    • oncology
  • Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC
    J. Roeper, S. Kurz, C. Grohé, F. Griesinger
    PMID: 33094641 Show Details link to full text
    Study

    Year

    2021

    Keywords
    • EGFR
    • NSCLC
    • tyrosine kinase inhibitor
    • oncology
  • Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial
    L. Zimmer, A. Krackhardt, E. S. Schultz, D. Goeppner, C. Assaf, D. Trebing, E. Livingstone, D. Schadendorf
    PMID: Show Details link to full text
    Study

    IMMU-Target

    Year

    2021

    Keywords
    • pembrolizumab
    • encorafenib
    • binimetinib
    • oncology
    • BRAF mutation
  • A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer
    M. Hecht, D. Hahn, P. Wolber, M. G. Hautmann, D. Reichert, S. Weniger, C. Belka, T. Bergmann, T. Göhler, M. Welslau, C. Große-Thie, O. Guntinas-Lichius, J. von der Grün, P. Balermpas, K. Orlowski, D. Messinger, K. G. Stenzel, R. Fietkau
    PMID: 34298628 Show Details link to full text
    Study

    SOCCER

    Year

    2021

    Keywords
    • cetuximab
    • head and neck cancer
    • oncology
  • Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
    BEAMing, circulating tumor DNA, clonal selection, colorectal cancer, digital droplet PCR, liquid biopsy, methylation WIF1 promotor, neoRAS wild-type
    PMID: 32766143 Show Details link to full text
    Study

    RAS Convert VP

    Year

    2020

    Keywords
    • colorectal cancer
    • liquid biopsy
    • neoRAS wild-type
    • oncology
Follow:
Page: 2/5